Trial reportDiabetes care2026
Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes: A Randomized Controlled Parallel Intervention Trial.
Trial report in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveTo investigate the effects of a sleep intervention (Sleep-Opt) compared with an attention control intervention (Healthy Living) on glycemic targets and psychological outcomes in adults with type 1diabetes (T1D). RESEARCH DESIGN AND
methodsAdults with T1D and short (<6.5 h/night) or irregular (variability of sleep duration ≥1 h) sleep were randomly assigned to either the Sleep-Opt (n = 73) or Healthy Living control (n = 71) intervention, both of which were remotely delivered in eight sessions for 12 weeks. Primary (A1C, continuous glucose monitoring [CGM], and objective sleep) and secondary (psychological and subjective sleep) outcomes were collected at baseline and 6, 12, and 24 weeks, with 12 weeks being a primary end point.
resultsA1C and CGM parameters at 12 weeks indicated no significant differences between groups. Sleep duration increased at 6 weeks in both groups, but no significant differences were observed between groups at any time point. Sleep-Opt participants had reduced diabetes distress (median difference -0.18 [95% CI -0.35, -0.01]) and improved subjective sleep quality (-0.96 [-0.17, -0.23]) compared with the Healthy Living group at 6 weeks but not at other time points. A significant interaction was found suggesting the effect of the intervention depended on baseline A1C level. At 12 weeks, the Sleep-Opt group with baseline A1C ≥7% had a lower A1C level than the Healthy Living group (marginal mean -0.32% [95% CI -0,64%, -0.005%]; -3.5 [95% CI -7.0, -0.1] mmol/mol; P = 0.047).
conclusionsSleep-Opt did not improve glycemic targets or sleep parameters, although sleep improved in both intervention groups. Glycemic benefits were observed in participants with suboptimal A1C, suggesting a possible role of sleep intervention in this patient group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.